Novartis Earns FDA Approval for Beovu

Novartis received the FDA’s approval for Beovu (brolucizumab) injection for treating wet age-related macular degeneration.

Wet AMD is a chronic, degenerative eye disease caused by an excess of vascular endothelial growth factor (VEGF), a protein that promotes the growth of abnormal blood vessels. Beovu inhibits VEGF to suppress their growth and limits the potential for fluid leakage into the retina.

The approval was based on the results of two phase 3 clinical trials that demonstrated an overall safety profile comparable to aflibercept.